Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Evolocumab (Repatha) vs Telmisartan: Evolocumab (Repatha) has the stronger overall evidence (4.5 vs 4.3/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Evolocumab (Repatha) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Evolocumab (Repatha) and Telmisartan have evidence — compare verdict strength side-by-side.
Standard approved dosing is 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly, under a clinician. A prescription drug; this is informational, not a recommendation.
any
Subcutaneous prefilled autoinjector (evolocumab)
Approved antihypertensive dosing is 20–80 mg once daily; the metabolic/PPARγ effects are most evident at the higher 80 mg (and study) doses, under a clinician. Not an approved metabolic or longevity regimen; blood pressure, kidney function, and potassium should be monitored.
morning
Oral tablet (telmisartan)
Weeks
Months to years
Weeks
Throughout use
Months to years
Weeks to months
Years
Throughout use
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
The New England journal of medicine (2017) · Rct · n=27564
FOURIER randomized ~27,564 patients with atherosclerotic cardiovascular disease on statin therapy
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
Circulation (2022) · Open label
FOURIER-OLE: open-label extension following patients on long-term evolocumab
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
JAMA (2016) · Rct
GLAGOV randomized statin-treated patients to evolocumab or placebo with serial intravascular ultrasound
Telmisartan, ramipril, or both in patients at high risk for vascular events.
The New England journal of medicine (2008) · Rct · n=25620
ONTARGET randomized 25,620 high-vascular-risk patients to ramipril, telmisartan, or both
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Lancet (London, England) (2008) · Rct · n=25620
Prespecified ONTARGET renal analysis of the same 25,620 patients
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
Lancet (London, England) (2008) · Rct · n=5926
TRANSCEND randomized 5,926 ACE-inhibitor-intolerant high-risk patients to telmisartan or placebo
Evolocumab (Repatha) has a higher evidence score (4.5/10 vs 4.3/10) and wins in 2 of 3 categories.
For support heart health, Evolocumab (Repatha) has a higher relevance score (80 vs 66).
No known interactions between Evolocumab (Repatha) and Telmisartan have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.